Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
AOP Orphan Pharmaceuticals Sweden AB
AB
Active
Org 5591698708
Köpsvängen 16, 168 67
Bromma
Wholesale of pharmaceutical and medical goods
·
NACE 4646
Est. 2018 · 7 years old
9 employees
Monitor
Share
Sweden
/
Companies
/
Wholesale of pharmaceutical and medical goods
/
AOP Orphan Pharmaceuticals Sweden AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
50M
37M
25M
12M
0M
2021: 28M
28M
2021
2022: 27M (-4% vs 2021)
27M
-4%
2022
2023: 28M (+4% vs 2022)
28M
+4%
2023
2024: 31M (+11% vs 2023)
31M
+11%
2024
2025: 40M (+29% vs 2024)
40M
+29%
2025
EBITDA
SEK millions
4M
3M
2M
1M
0M
2021: 1M
1M
2021
2022: 1M (0% vs 2021)
1M
0%
2022
2023: 1M (0% vs 2022)
1M
0%
2023
2024: 2M (+100% vs 2023)
2M
+100%
2024
2025: 3M (+50% vs 2024)
3M
+50%
2025
Income statement
SEK thousands
Item
2025
2024
2023
2022
2021
Revenue
40 409
31 307
28 371
27 450
27 648
Staff expenses
−23 415
−17 599
−15 991
—
—
EBITDA
2 837
1 790
815
885
972
Depreciation & amort.
−18
—
—
−0
−0
EBIT
2 818
1 790
815
885
972
Net financials
2
3
−64
−63
−12
Profit before tax
2 821
1 793
751
822
959
Tax
−693
−435
−211
−270
−220
Net profit
2 128
1 359
540
552
739
Balance sheet
SEK thousands
Item
2025
2024
2023
2022
2021
Total assets
13 160
8 461
7 211
10 281
14 213
Equity
6 036
3 946
2 587
2 064
1 499
Long-term debt
—
—
—
0
1 844
Short-term debt
7 124
4 515
4 623
8 217
10 870
Total debt
7 124
4 515
4 623
8 217
12 714
Financial ratios
5-year trend
EBITDA margin
7,0 %
This company
15,8 %
Market median
This company
Market median
56% below market
2021
2025
Equity ratio
45,9 %
This company
38,2 %
Market median
This company
Market median
20% above market
2021
2025
Return on equity
35,3 %
This company
18,4 %
Market median
This company
Market median
92% above market
2021
2025
Net profit margin
5,3 %
This company
8,1 %
Market median
This company
Market median
35% below market
2021
2025
Asset turnover
3,07×
This company
1,12×
Market median
This company
Market median
174% above market
2021
2025
Debt / equity
1,18×
This company
0,62×
Market median
This company
Market median
90% above market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
More on AOP Orphan Pharmaceuticals Sweden AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
